Gestogesic Tablet SR contains Progesterone 200 mg, a naturally occurring steroid hormone essential for regulating the menstrual cycle and maintaining pregnancy. This sustained-release formulation ensures a steady release of progesterone, enhancing therapeutic efficacy and patient compliance. Progesterone plays a critical role in preparing the endometrium for implantation, supporting early pregnancy, and preventing preterm labor. Gestogesic Tablet SR is indicated for the treatment of progesterone deficiency-related conditions such as amenorrhea, abnormal uterine bleeding, and luteal phase support in assisted reproductive technologies. It is also employed in hormone replacement therapy to counterbalance estrogen effects in menopausal women. The sustained-release mechanism allows for once-daily dosing, minimizing fluctuations in hormone levels and reducing side effects. Patients should use Gestogesic Tablet SR under medical supervision, with dosage tailored to individual clinical needs. Contraindications include known hypersensitivity to progesterone, unexplained vaginal bleeding, active thromboembolic disorders, and certain hormone-sensitive cancers. Common adverse effects may include headache, breast tenderness, mood changes, and gastrointestinal discomfort. Regular monitoring is advised during therapy to assess efficacy and detect potential adverse reactions. Gestogesic Tablet SR should be stored in a cool, dry place away from direct sunlight and out of reach of children.